Sir: Winchester et al two decades ago proposed that IgG rheumatoid factor (RF) could be locally produced in plasma cells that line the synovium.' We conducted a short study looking at paired samples of synovial fluid (from the knee joint) and serum from patients with definite rheumatoid arthritis to determine if the production of IgG RF is localised in the synovial fluid. Thirty six serum samples and synovial fluids were obtained from patients diagnosed with rheumatoid arthritis, all collected within one day of each other. The synovial fluids were treated with hyaluronidase enzyme2 (Sigma, USA) before testing. Serum samples and synovial fluids were also tested for the presence of IgG antibody to adenovirus. Adenovirus antibody levels have been used to establish local production of antibody in cerebrospinal fluid in syphilis3 and HIV4; this antibody is common and can be used to determine if non-specific 'leaking' of immunoglobulins from serum has occurred. This should be more accurate than comparing total levels of IgG, which are difficult to measure in low concentrations.
An enzyme immunoassay (EIA) was developed for the detection of IgG Coichicine myoneuropathy and renal dysfunction* Sir: Colchicine has been used in the treatment of gout and other diseases for over 200 years.
Unusually high dosing regimens have resulted in multiorgan toxicity affecting the haemopoietic, renal, nervous, dermatological, and musculoskeletal systems.' 2 Recently, a myoneuropathy has been noted in elderly patients taking low doses of colchicine over months to years.3 All patients had underlying chronic renal insufficiency, which is considered an important component of the syndrome. We report the development of colchicine myoneuropathy in a woman with a transient prerenal illness. A 75 year old woman presented with a three week history of progressive proximal muscle weakness. The onset ofher symptoms followed a 10 day diarrhoeal illness that spontaneously resolved. Her medical history included longstanding hypertension, degenerative joint disease, and suspected calcium pyrophosphate deposition disease, for which she had been treated with oral colchicine, 0-6 mg twice daily, over the preceding 16 months. Other drugs included a thiazide diuretic taken three times daily. Physical examination showed an elderly woman weighing 61-4 kg who appeared well. Motor testing disclosed weakness of the shoulder and pelvic girdle muscles with normal distal strength, and results of a neurological examination were normal. Laboratory studies showed a creatine kinase of 646 IU/I (normal range 0-170 IU/l), and a Westergren sedimentation rate of 10 mm/h. Blood urea was 13-2 mmol/l and serum creatinine 132-6 iLmol/l. Renal function studies six months earlier had been within normal limits: blood urea 6-4 mmol/l and serum creatinine 106 1 Itmol/l. Electromyography showed myopathic changes characterised by resting membrane instability, positive sharp waves, fibrillations, and decreased amplitude and duration of potentials in proximal muscles. Nerve conduction studies were consistent with a mild polyneuropathy of the legs. A muscle biopsy showed vacuolation of 30% of myofibres without necrosis, inflammatory infiltrates, atrophy, or inclusion bodies (figure). Treatment with colchicine and diuretic was discontinued. Ten days later her motor strength had returned to normal and the serum creatine kinase was 35 IU/I. Blood urea was 6-1 mmol/l and serum creatinine 114-9 ,tmol/l.
In the nervous system colchicine interferes with neurotubule assembly causing a disruption of axonal transport.4 This probably accounts for the mild polyneuropathy seen in affected patients; however, the mechanism of injury in muscle, is less clear. In rat skeletal muscle an accumulation of 'large sarcoplasmic membranous bodies'-with presumed autophagic activity-appears two to three days after the intraperitoneal injection of colchicine and is coincident with clinical weakness.5 In the arterial smooth muscle cells of rats colchicine causes structural and functional changes, including the increased appearance of autophagic vacuoles and lysosomes.6 In humans electron microscopy of proximal skeletal muscle from patients with colchicine myopathy shows abnormal accumulation of lysosomes and autophagic vacuoles.3 An anatomical linkage between lysosomes and microtubules has been demonstrated in cultured fibroblast studies.7 It seems likely that colchicine disrupts the microtubular cytoskeleton that directs the movement and function of intracellular organelles including lysosomes and autophagic vacuoles. Ironically, however, microtubules have not been clearly shown in human adult skeletal muscle. Whether colchicine exerts its myotoxic effects through intracellular microtubular disruption or by a yet undisclosed mechanism remains to be shown. 
